bioAffinity Technologies Stock

bioAffinity Technologies FCF/Debt

The Free Cash Flow to Debt Ratio of bioAffinity Technologies (BIAF) as of Aug 19, 2026 is -711.89 %. In the previous year, Free Cash Flow to Debt Ratio was -504.68 % — a change of 41.06% (lower).

FCF/Debt

-711.89 %

YoY

41.06%

Last updated:

Free Cash Flow to Debt Ratio of bioAffinity Technologies is 2026 -711.89 % . Free Cash Flow to Debt Ratio of bioAffinity Technologies was 2025 -504.68 % . It decreases by 41.06% lower compared to the previous year.
Access this data via the Eulerpool API

bioAffinity Technologies Stock analysis

What does bioAffinity Technologies do? bioAffinity Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about bioAffinity Technologies stock

Free Cash Flow to Debt Ratio of bioAffinity Technologies is -711.89 % in 2026.

Free Cash Flow to Debt Ratio of bioAffinity Technologies changed from -504.68 % to -711.89 %, representing a 41.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio bioAffinity Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's bioAffinity Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — bioAffinity Technologies

All Key Metrics — bioAffinity Technologies